|Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer|
Authors: Ajai Pal, Ateeq Ahmad, Sumsullah Khan, Isamu Sakabe, Chuanbo Zhang, Usha N. Kasid, Imran Ahmad
Pharmacokinetics, Safety and Efficacy Department, NeoPharm Inc., Research and Development, Waukegan, IL 60085, USA
Raf-1, a protein serine-threonine kinase, plays a critical role in mitogen-activated protein kinase kinase (MKK/MEK)- mitogen-activated protein kinase (extracellular signal-regulated kinase) (MAPK/ERK) pathways. We show here that systemically delivered novel cationic cardiolipin liposomes (NeoPhectin-AT™) containing a small interfering RNA (siRNA) against Raf-1 silence the expression of Raf-1 in tumor tissues and inhibit tumor growth in xenograft model of human prostate cancer. The knockdown of Raf-1 expression by siRNA is also associated with down-regulation of cyclin D1 expression in vivo.